UCB Stock Overview
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
UCB SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €82.12 |
52 Week High | €88.80 |
52 Week Low | €67.58 |
Beta | 0.33 |
1 Month Change | -0.024% |
3 Month Change | -1.86% |
1 Year Change | 18.26% |
3 Year Change | -16.02% |
5 Year Change | 6.10% |
Change since IPO | 1,697.25% |
Recent News & Updates
Is UCB (EBR:UCB) Using Too Much Debt?
Aug 07Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?
Jun 02Recent updates
Is UCB (EBR:UCB) Using Too Much Debt?
Aug 07Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?
Jun 02UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's
Apr 05Does UCB (EBR:UCB) Have A Healthy Balance Sheet?
Apr 03Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly
Dec 05These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well
Sep 05Does UCB (EBR:UCB) Have A Healthy Balance Sheet?
Jun 06UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year
Apr 23UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's
Apr 09UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91
Mar 26Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly
Dec 23Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?
Dec 05Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly
Sep 23UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate
Sep 05UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jul 31Is UCB (EBR:UCB) A Risky Investment?
Jun 21UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price
May 13Is UCB (EBR:UCB) Using Too Much Debt?
Mar 18Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?
Feb 28UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price
Feb 10What Makes UCB SA (EBR:UCB) A Great Dividend Stock?
Jan 20Is UCB SA (EBR:UCB) Popular Amongst Institutions?
Jan 07UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?
Dec 23With EPS Growth And More, UCB (EBR:UCB) Is Interesting
Dec 04UCB SA's (EBR:UCB) Share Price Not Quite Adding Up
Sep 17UCB's (EBR:UCB) Earnings Are Growing But Is There More To The Story?
Aug 31Here's What UCB SA's (EBR:UCB) Shareholder Ownership Structure Looks Like
Aug 06Shareholder Returns
UCB | BE Pharmaceuticals | BE Market | |
---|---|---|---|
7D | -2.5% | -2.0% | -1.1% |
1Y | 18.3% | 18.1% | 9.0% |
Return vs Industry: UCB matched the Belgian Pharmaceuticals industry which returned 18% over the past year.
Return vs Market: UCB exceeded the Belgian Market which returned 6.8% over the past year.
Price Volatility
UCB volatility | |
---|---|
UCB Average Weekly Movement | 2.6% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 3.3% |
10% most volatile stocks in BE Market | 6.8% |
10% least volatile stocks in BE Market | 2.1% |
Stable Share Price: UCB is less volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: UCB's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1925 | 8,600 | Jean-Christophe Tellier | https://www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.
UCB SA Fundamentals Summary
UCB fundamental statistics | |
---|---|
Market Cap | €15.58b |
Earnings (TTM) | €332.00m |
Revenue (TTM) | €5.11b |
46.9x
P/E Ratio3.0x
P/S RatioIs UCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UCB income statement (TTM) | |
---|---|
Revenue | €5.11b |
Cost of Revenue | €1.63b |
Gross Profit | €3.48b |
Other Expenses | €3.15b |
Earnings | €332.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 28, 2024
Earnings per share (EPS) | 1.75 |
Gross Margin | 68.09% |
Net Profit Margin | 6.50% |
Debt/Equity Ratio | 30.3% |
How did UCB perform over the long term?
See historical performance and comparison